Krishna Institute of Medical Sciences Limited

rs,

nager, Department of Corporate Services Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 543308 ISIN: INE967H01025 Dear Sir, Sub: Investo

Rs. 45,000

entre” in Hyderabad with 50 beds and performed heart surgeries at an unimaginable low cost of just Rs. 45,000 only. Dr. Rao never turned away any patient from the hospital for want of money. The brand “Krishna

rs 6

h as Financial counseling tool which uses AI to help patients with surgery costings among many others 6 Private & Confidential Board of Directors Dr. Bhaskara Rao Bollineni Chairman & Managing Director

6.8%

ctor 7 Private & Confidential Shareholding Pattern - As on 30th September, 2025 Retail Pre IPO, 6.8% Retail & Others, 9.7% Promoters, 34.1% FII, 16.7% DII, 32.7% Top Share Holders - DII's & FII'

9.7%

dential Shareholding Pattern - As on 30th September, 2025 Retail Pre IPO, 6.8% Retail & Others, 9.7% Promoters, 34.1% FII, 16.7% DII, 32.7% Top Share Holders - DII's & FII's No of Shares Share H

34.1%

ing Pattern - As on 30th September, 2025 Retail Pre IPO, 6.8% Retail & Others, 9.7% Promoters, 34.1% FII, 16.7% DII, 32.7% Top Share Holders - DII's & FII's No of Shares Share Holding % Category

16.7%

- As on 30th September, 2025 Retail Pre IPO, 6.8% Retail & Others, 9.7% Promoters, 34.1% FII, 16.7% DII, 32.7% Top Share Holders - DII's & FII's No of Shares Share Holding % Category 13,64,89,3

32.7%

September, 2025 Retail Pre IPO, 6.8% Retail & Others, 9.7% Promoters, 34.1% FII, 16.7% DII, 32.7% Top Share Holders - DII's & FII's No of Shares Share Holding % Category 13,64,89,330 34.1%

6.0%

92,05,275 78,50,000 Amansa Holdings Private Limited 77,04,880 Invesco MF 73,16,746 6.0% 5.3% 4.3% 3.0% 2.9% 2.6% 2.3% 2.0% 1.9% 1.8% DII DII DII DII FII DII F

5.3%

,275 78,50,000 Amansa Holdings Private Limited 77,04,880 Invesco MF 73,16,746 6.0% 5.3% 4.3% 3.0% 2.9% 2.6% 2.3% 2.0% 1.9% 1.8% DII DII DII DII FII DII FII

4.3%

78,50,000 Amansa Holdings Private Limited 77,04,880 Invesco MF 73,16,746 6.0% 5.3% 4.3% 3.0% 2.9% 2.6% 2.3% 2.0% 1.9% 1.8% DII DII DII DII FII DII FII DII

3.0%

0,000 Amansa Holdings Private Limited 77,04,880 Invesco MF 73,16,746 6.0% 5.3% 4.3% 3.0% 2.9% 2.6% 2.3% 2.0% 1.9% 1.8% DII DII DII DII FII DII FII DII FII

“Tulsa-Pro System A non- invasive procedure that uses real-time MRI guidance to precisely deliver thermal ablation for treating BPH (Benign Prostatic Hyperplasia) and prostate cancer, preserving surrounding healthy tissue.”

“Best Super-Specialty Hospital in Telangana National Quality Excellence Awards 2020 Only Hospital in Telangana to get NABH Accredition for Emergency Department 2021 Ranked No.1 in Hyderabad for Cardiology, Neurosciences, Nephrology & Emergency Times Health Survey Times of India 11 Private & ConfidentialINTERNATIONAL ACCREDITATION Consistent Performer over 2 decades (Rupees in Millions) 30,670 7,590 25,143 22,235 CAGR: 26.9% 11,287 16,711 6,200 5,766 CAGR: 29.7% 5,217 2,412 263 2005 No.”

“Regional Market Leadership Strategy: Focused expansion to establish dominant presence in target geographies and accelerate new business growth.”

“These Strategic levers underpin the next phase of expansion – Adding 2100+ Beds through Green Field Projects & O&M Opportunities 14 Private & Confidential Q2 FY26 Updates 15 Private & Confidential Financial & Operational Highlights - 1/2 (Rupees in Millions) FINANCIAL HIGHLIGHTS Q2 FY26 Consolidated • Total Revenue of INR 9,649 Mns, a growth of 23.3% on YoY and 9.8% on QoQ basis.”

“• EBITDA Margin at 21.6% vs 28.5% in Q2 FY25 and 22.7% in Q1 FY26.”

“• PAT at INR 720 Mns in Q2 FY26 against INR 1,207 Mns and INR 850 Mns in Q2 FY25 and Q1 FY26 respectively.”

“• Consolidated EPS for Q2 FY26 of INR 1.67, a degrowth of 37.7% on YoY basis and 14.7% on QoQ basis respectively.”

“• Consolidated Key Financials figures are as follows (Rs in Mns) : Particulars Total Income Less : Other Income Revenue from Operations PBT* Add : Interest Add : Depreciation Less : Gain or loss on fair valuation of Call option Consoldiated - Q2 FY26 Results Q2 FY26 Q1 FY26 Q2 FY25 QoQ YoY 9,649 8,787 7,823 9.8% 23.3% 42 9,607 968 450 661 -3 71 8,716 1,137 326 534 - 50 7,773 1,622 199 410 - 10.2% -14.9% 23.6% -40.3% Reported EBITDA (Incl.”

“Peripheral Drainage Strengthening: Expanded regional reach by initiating 7–8 peripheral OPDs; plan to scale up to 20 OPDs this quarter to strengthen patient inflow from surrounding districts.”

VISION

1

OUR MISSION

1

VISION

To be the most preferred healthcare services brand by providing affordable care and best clinical outcomes to patients. And to be the best place to work for doctors and employees.

OUR MISSION

Provide affordable quality care to our patients with patient-centric systems and processes. Enable clinical outcome-driven excellence by engaging modern medical technology. Provide a strong impetus for doctors to pursue academics and medical research. S T N ATIE P Most Preferred Healthcare Provider DOCTORS EMPLOYEES INVESTO RS Affordable Quality Care Best-in-Class Facilities Patient Centric Systems & Processes Clinical Outcome Driven Excellence Latest Medical Technology Strong Academics & Research Oriented Enriching Atmosphere Collaborative Culture Growth Driven Career Approach Transparent Governance Strong Operational Performance Consistent Growth 3 Private & Confidential Multi Specialty Care Brain • Neurology • Neurosurgery • Psychiatry • Neuro Rehabilitation Heart • Cardiology • Cardiac Surgery • Vascular Surgery • Heart Transplant • Cardio Rehabilitation Lung • Pulmonology • Interventional Pulmonology • Thoracic surgery • Lung Transplant ENT • Ear • Nose • Throat • Head and Neck Su